1Mirus Corporation, 505 S Rosa Road, Madison, WI 53719, USA. jimh@genetransfer.com
Developing stable non-viral DNA particles for gene therapy is challenging. Recent advances in understanding in vivo barriers enable rational design of polymer/DNA particles (polyplexes) to resist aggregation and inactivation.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: